Table 1.
Patients and treatment characteristics of the entire study cohort
| Factors | Groups | n | (%) |
| Gender | Male | 108 | (97.2) |
| Female | 3 | (2.7) | |
| Age (years) | Median (range) | 69 | (40–80) |
| PS | 0 | 93 | (83.8) |
| 1 | 17 | (15.3) | |
| 2 | 1 | (0.9) | |
| BMI (kg/m2) | Median (range) | 22.2 | (15.1–31.2) |
| Smoking status | Yes | 95 | (85.6) |
| No | 16 | (14.4) | |
| Pack-year | 40 | (0–100) | |
| Larynx | Glottis | 82 | (73.9) |
| Supraglottis | 8 | (7.2) | |
| Subglottis | 2 | (1.8) | |
| Hypopharynx | Piriform sinus | 15 | (13.5) |
| Posterior pharyngeal wall | 1 | (0.9) | |
| cTstage | 1 | 48 | (43.2) |
| 2 | 47 | (42.3) | |
| 3 | 10 | (9) | |
| 4 | 4 | (3.8) | |
| cNstage | 0 | 85 | (76.6) |
| 1 | 16 | (14.4) | |
| 2 | 10 | (8.1) | |
| Hypertension | Yes | 50 | (45.0) |
| No | 61 | (55.0) | |
| Diabetes mellitus | Yes | 28 | (25.2) |
| No | 83 | (74.8) | |
| Dyslipidemia | Yes | 37 | (33.3) |
| No | 74 | (66.7) | |
| Cardiovascular disease | Yes | 23 | (20.7) |
| No | 88 | (79.3) | |
| Antiplatelet therapy | Yes | 22 | (19.8) |
| No | 89 | (80.2) | |
| Radiation dose (Gy) | Total dose, Median (range) | 66 | (60–74) |
| Dose per fraction (Gy), Median (range) | 2 | (1.8–2.4) | |
| Radiation field | WN | 29 | (26.1) |
| Box | 82 | (73.9) | |
| Chemotherapy | Yes | 48 | (43.2) |
| CBDCA+UFT | 13 | (11.7) | |
| CDDP | 16 | (14.4) | |
| FP | 9 | (8.1) | |
| FN | 6 | (5.4) | |
| Others | 4 | (3.6) | |
| No | 63 | (56.8) |
PS: performance status
BMI: body mass index
WN: whole neck field including subclinical lymph node
Box; parallel-opposed fields with individualized wedge-filtered technique, 5 × 5 or 6 × 6 cm; CBDCA, carboplatin; UFT, tegafur/uracil; CDDP, cisplatin; FP, combined with the use of CDDP and 5-fluorouracil; FN, combined with the use of nedaplatin and 5-fluorouracil